{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-027373","form_type":"8-K","ticker":"UNCY","cik":"0001766140","company_name":"Unicycive Therapeutics, Inc.","filed_at":"2024-03-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.449236+00:00","generated_at":"2026-06-04T05:27:44.282154+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Unicycive reports FY2023 net loss of $31.4M; OLC topline data expected Q2 2024","bullets":["FY2023 net loss $31.4M ($1.28/share) vs $18.1M ($1.20/share) in FY2022.","Cash $9.7M at Dec 31, 2023; subsequent $50M private placement extends runway into 2026.","Pivotal OLC trial enrollment completed; topline data expected in Q2 2024.","UNI-494 granted FDA Orphan Drug Designation for delayed graft function; Phase 1 SAD complete, MAD ongoing.","R&D expenses $12.9M, G&A $8.5M; licensing revenue $0.7M."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-027373","json":"https://secwatch.observer/filing/0001213900-24-027373.json","markdown":"https://secwatch.observer/filing/0001213900-24-027373.md","text":"https://secwatch.observer/filing/0001213900-24-027373.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1766140/000121390024027373/0001213900-24-027373-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1766140/000121390024027373/ea0202810-8k_unicycive.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T05:27:44.282154+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d79abc2bf66350288e4171cbc7a85a647b6f3bc2","claim":"Unicycive Therapeutics, Inc. reported the year ended December 31, 2023 results: net income Net loss attributable to common stockholders for the year ended December 31, 2023 was $31.4 million, or $1.28 per share.","evidence_excerpt":"Net loss attributable to common stockholders for the year ended December 31, 2023 was $31.4 million, or $1.28 per share of common stock, compared to a net loss of $18.1 million, or $1.20 per share of common stock, for the same period in 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1766140/000121390024027373/0001213900-24-027373-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2023"},{"label":"Net income","value":"Net loss attributable to common stockholders for the year ended December 31, 2023 was $31.4 million, or $1.28 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}